Morgan Stanley Maintains Equal-Weight on Sigilon Therapeutics, Raises Price Target to $91
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Harrison maintains an Equal-Weight rating on Sigilon Therapeutics (NASDAQ:SGTX) and raises the price target from $2 to $91.
May 25, 2023 | 12:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Morgan Stanley maintains an Equal-Weight rating on Sigilon Therapeutics and raises the price target from $2 to $91.
The news directly mentions Sigilon Therapeutics (NASDAQ:SGTX) and the significant increase in the price target from $2 to $91 by Morgan Stanley analyst Matthew Harrison. This could lead to a positive short-term impact on the stock price as investors may see this as a sign of increased confidence in the company's prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100